Abstract
Retinopathy of prematurity is a potentially blinding disease, which is associated with low neonatal IGF-I serum concentrations and poor growth. In severe cases impaired retinal vessel growth is followed by pathologic neovascularization, which may lead to retinal detachment. IGF-I may promote growth even in catabolic states. Treating preterm infants with recombinant human (rh) IGF-I to concentrations normally found during gestation has been suggested to have a preventative effect on ROP. A recent phase 2 study treating infants (gestational age between 23weeks+0days and 27weeks +6days) with rhIGF-I/IGF binding protein-3 until 30 postmenstrual weeks showed no effect on ROP but a 53% reduction in severe bronchopulmonary dysplasia and 44% reduction in severe intraventricular hemorrhage. Oxygen is a major risk factor for ROP and during the phase 2 study oxygen saturation targets were increased to 90-95%, due to national guidelines, which might have affected ROP rate and severity making increased IGF-I a weaker preventative factor for ROP.
| Original language | English |
|---|---|
| Pages (from-to) | 75-80 |
| Number of pages | 6 |
| Journal | Growth Hormone and IGF Research |
| Volume | 30-31 |
| DOIs | |
| Publication status | Published - Oct 11 2016 |
Fingerprint
Keywords
- Review
- Journal Article
Cite this
IGF-I in the clinics : Use in retinopathy of prematurity. / Hellström, Ann; Ley, David; Hansen-Pupp, Ingrid; Hallberg, Boubou; Ramenghi, Luca A; Löfqvist, Chatarina; Smith, Lois E H; Hård, Anna Lena.
In: Growth Hormone and IGF Research, Vol. 30-31, 11.10.2016, p. 75-80.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - IGF-I in the clinics
T2 - Use in retinopathy of prematurity
AU - Hellström, Ann
AU - Ley, David
AU - Hansen-Pupp, Ingrid
AU - Hallberg, Boubou
AU - Ramenghi, Luca A
AU - Löfqvist, Chatarina
AU - Smith, Lois E H
AU - Hård, Anna Lena
N1 - Copyright © 2016 The Authors. Published by Elsevier Ltd.. All rights reserved.
PY - 2016/10/11
Y1 - 2016/10/11
N2 - Retinopathy of prematurity is a potentially blinding disease, which is associated with low neonatal IGF-I serum concentrations and poor growth. In severe cases impaired retinal vessel growth is followed by pathologic neovascularization, which may lead to retinal detachment. IGF-I may promote growth even in catabolic states. Treating preterm infants with recombinant human (rh) IGF-I to concentrations normally found during gestation has been suggested to have a preventative effect on ROP. A recent phase 2 study treating infants (gestational age between 23weeks+0days and 27weeks +6days) with rhIGF-I/IGF binding protein-3 until 30 postmenstrual weeks showed no effect on ROP but a 53% reduction in severe bronchopulmonary dysplasia and 44% reduction in severe intraventricular hemorrhage. Oxygen is a major risk factor for ROP and during the phase 2 study oxygen saturation targets were increased to 90-95%, due to national guidelines, which might have affected ROP rate and severity making increased IGF-I a weaker preventative factor for ROP.
AB - Retinopathy of prematurity is a potentially blinding disease, which is associated with low neonatal IGF-I serum concentrations and poor growth. In severe cases impaired retinal vessel growth is followed by pathologic neovascularization, which may lead to retinal detachment. IGF-I may promote growth even in catabolic states. Treating preterm infants with recombinant human (rh) IGF-I to concentrations normally found during gestation has been suggested to have a preventative effect on ROP. A recent phase 2 study treating infants (gestational age between 23weeks+0days and 27weeks +6days) with rhIGF-I/IGF binding protein-3 until 30 postmenstrual weeks showed no effect on ROP but a 53% reduction in severe bronchopulmonary dysplasia and 44% reduction in severe intraventricular hemorrhage. Oxygen is a major risk factor for ROP and during the phase 2 study oxygen saturation targets were increased to 90-95%, due to national guidelines, which might have affected ROP rate and severity making increased IGF-I a weaker preventative factor for ROP.
KW - Review
KW - Journal Article
U2 - 10.1016/j.ghir.2016.09.005
DO - 10.1016/j.ghir.2016.09.005
M3 - Article
C2 - 27720550
VL - 30-31
SP - 75
EP - 80
JO - Endocrinology and Metabolism, Supplement
JF - Endocrinology and Metabolism, Supplement
SN - 1096-6374
ER -